Elution & Antibody Identification, RBC
Also known as: IRL-ELU
Use
The Elution & Antibody Identification test is designed to determine the specificity of antibodies that coat the red blood cells (RBCs) in vivo. It helps in identifying the presence of antibodies in patients, which may be indicative of hemolytic anemia or other immune-related blood disorders. This test is crucial in the management of patients who exhibit signs of transfusion reactions or hemolytic disease of the newborn.
Special Instructions
This test includes the resolution of a Positive Direct Antiglobulin Test (DAT). It is performed from Monday to Friday and requires careful attention to specimen collection and transportation requirements, as specified in the provided instructions.
Limitations
The Elution & Antibody Identification test may have limitations related to the detection of weakly reactive or low-affinity antibodies. Antibodies that do not strongly bind to the RBCs or are present in low concentrations may not be identified accurately. The test is also subject to interference from certain medications or conditions that affect antibody binding.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Hemagglutination)
Biomarkers
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
2 mL
Container
Lavender (K2EDTA) or Pink (K2EDTA)
Storage Instructions
Refrigerated
Causes for Rejection
Separator or gel tubes
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 1 week |
| Frozen | Unacceptable |